HelloFresh and No Kid Hungry Launch Hunger Hero Campaign to Combat Summer Hunger
NEW YORK--(BUSINESS WIRE)--HelloFresh, the world's leading meal kit provider, and No Kid Hungry, a campaign focused on ending childhood hunger, announced today the 'Hunger Hero' campaign to raise awareness of rising hunger across the US. The meal kit brand is tapping celebrated online chefs and dedicated hunger relief advocates, including Tini Younger, Eitan Bernath and Becca and Justin Schwartz, to serve as ambassadors of the campaign and raise awareness of childhood food insecurity during the summer months, inspiring others to join in the cause.
In the US, 1 in 5 kids face hunger. This staggering reality is only heightened during the summer months.
Share
In the US, 1 in 5 kids face hunger. This staggering reality is only heightened during the summer months when kids are out of school and lose access to the dependable nutrition they get at school during the academic year. Impending cuts to SNAP and other critical programs, coupled with a looming crisis for food banks, threaten to make the issue even worse.
Galvanizing Hunger Heroes to Help Fight Food Insecurity
Through a combination of social- and event-led initiatives, the Hunger Hero campaign will provide individuals with a call-to-action to help address childhood hunger in their own communities.
HelloFresh kicks off the program today with a series of distribution events in New York City, NY; Atlanta, GA; and Phoenix, AZ where families can access free HelloFresh meal kits filled with nutritious, family-friendly recipes, along with vital resources on summer EBT, SNAP benefits and information on where to access support through No Kid Hungry. Each event will be joined by a notable 'Hunger Hero,' an influencer, chef, and or 'foodie' who is actively committed to fighting food insecurity in their own communities. Tini Younger, who volunteers in her own backyard at Atlanta Mission, Eitan Bernath, a high-level supporter of the United Nations World Food Programme; and Becca and Justin Schwartz, who actively volunteer with Feed My Starving Children by hosting community volunteer events with their followers, will all serve as Hunger Heroes, providing assistance and awareness about the issue.
Beyond hosting these events, each Hunger Hero will call upon their followers to commit to fighting hunger — whether through donating to No Kid Hungry, volunteering at a local food bank or even simply raising awareness in their own communities. For every like, share, or comment on campaign-related posts, HelloFresh will make a donation to No Kid Hungry in support of their vital work feeding families year-round up to $10,000 from June through August.
The meal kit brand will also be running a social media campaign spotlighting everyday hunger heroes — including food bank leaders and educators — to spotlight the important work they do every day and inspire the brand's followers to join in the cause.
'From my time volunteering at Atlanta Mission, I've met many families trying their best, but struggling to put meals on the table,' said viral chef Tini Younger. 'Fighting food insecurity is deeply important to me. Being a part of this campaign is not just about food. It's about dignity, joy and the chance for kids to be kids.'
'Every day, we're witnessing more families struggling with hunger — and during the summer months, the need becomes even more urgent,' said Adam Kalikow, Senior Vice President and Managing Director at HelloFresh US. 'That's why we're doubling down on our efforts to help close the summer hunger gap. By partnering with some notable 'hunger heroes' like Tini, Eitan, Becca and Justin, we're able to bring more attention to this growing issue while making a tangible impact. We invite everyone to get involved and look forward to spotlighting hunger heroes across the country — those stepping up and making a real difference in their communities.'
'We're incredibly thankful for the continued support from HelloFresh to combat childhood food insecurity,' said Allison Shuffield, Managing Director of Corporate Partnerships. 'At a time of increased need, the support from corporations like HelloFresh is that much more important to ensure children are not going hungry this summer.'
To learn more about how HelloFresh and No Kid Hungry are fighting childhood food insecurity and to join the Hunger Hero movement in the action, please visit hellofresh.com/pages/nokidhungry or @HelloFresh on social media.
ABOUT HELLOFRESH
HelloFresh is the world's leading meal-kit company, providing customers with fresh, high-quality ingredients to cook delicious meals at home. By delivering pre-portioned ingredients and easy-to-follow recipes directly to customers' doors, HelloFresh helps busy individuals and families enjoy home-cooked meals without the hassle of meal planning and grocery shopping. HelloFresh was voted the Most Trusted Meal Kit Delivery Service in America from 2021 through 2023 by Newsweek. For more information, visit www.hellofresh.com or follow HelloFresh on Facebook, X, Instagram, or TikTok.
ABOUT HELLOFRESH GROUP
The HelloFresh Group is a global food solutions group and the world's leading meal kit provider. The HelloFresh Group consists of eight brands that provide customers with high quality food and recipes for different meal occasions including HelloFresh, Green Chef, EveryPlate, Chefs Plate, Factor, Youfoodz, The Pets Table and Good Chop. The Company was founded in Berlin in November 2011 and operates in the USA, the UK, Germany, the Netherlands, Belgium, Luxembourg, Australia, Austria, Switzerland, Canada, New Zealand, Sweden, France, Denmark, Norway, Italy, Ireland and Spain. In Q1 2024 HelloFresh Group delivered over 272 million meals globally. HelloFresh SE went public on the Frankfurt Stock Exchange in November 2017 and is currently traded on the MDAX (Mid-Cap German Stock Market Index). For more information, visit www.hellofreshgroup.com.
ABOUT NO KID HUNGRY
No child should go hungry in America. But millions of kids in the United States live with hunger. No Kid Hungry is working to end childhood hunger by helping launch and improve programs that give all kids the healthy food they need to thrive. This is a problem we know how to solve. No Kid Hungry is a campaign of Share Our Strength, an organization committed to ending hunger and poverty.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
City of Hope Experts Present Pioneering Research at 2025 American Diabetes Association Conference
LOS ANGELES--(BUSINESS WIRE)--Scientists with City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the United States, and a leading research center for diabetes and other life-threatening illnesses, presented their latest research findings at the American Diabetes Association's 85th Scientific Sessions, June 20-23, 2025, at the McCormick Place Convention Center in Chicago. Scientists with City of Hope presented their latest research findings at the American Diabetes Association's 85th Scientific Sessions, June 20-23, 2025, at the McCormick Place Convention Center in Chicago. Share 'City of Hope studies featured at this year's ADA meeting offer remarkable new insights that help demystify the molecular and cellular mechanisms of diabetes, pointing to new translational approaches and innovative therapies to prevent and treat the disease,' said Rama Natarajan, Ph.D., deputy director of the Arthur Riggs Diabetes & Metabolism Research Institute at City of Hope. 'The breadth of our research reflects City of Hope's legacy of excellence in breakthrough diabetes science.' Guarding Beta Cells from Autoimmune Attacks Beta cells are specialized endocrine cells in the pancreas that make and release insulin. Protection by internal energy factories called mitochondria enables each cell to produce the perfect dose of insulin to maintain normal blood glucose levels. When mitochondrial performance goes awry, however, the malfunction may trigger inflammation and immune response, leading to disease. Now, a City of Hope study led by Geming Lu, M.D., assistant research professor, discovered that a protein called BNIP3 plays a critical role in preserving mitochondrial health and reducing the organisms' ability to induce immune responses in type 1 diabetes. Using a preclinical model, Dr. Lu and his colleagues found that BNIP3 declines as diabetes worsens, disrupting beta cells' ability to make insulin and damaging cellular regions linked to inflammation. Various tests showed a drop in insulin and related proteins that support beta cell development and function. When the researchers treated the beta cell with a substance that mimicked cellular signals, it elevated proteins that invoked an immune response. Boosting BNIP3 quieted the body's immune response to the treatment. Conversely, reducing BNIP3 in the beta cells activated signaling pathways that help fight infections. 'When BNIP3 drops or goes missing in the beta cells, they start sending out a strong SOS that can trigger autoimmune attacks,' said Dr. Lu. 'Restoring BNIP3 helps calm these distress signals down.' That balance could prove critical in preventing or slowing cellular destruction in type 1 diabetes, he observed. 'Our research suggests that BNIP3 acts like a guardian for beta cells, preventing them from attracting unwanted attention from the immune system,' said Dr. Lu. The findings open up exciting possibilities for future therapies. 'If we can figure out how to boost BNIP3 activity — or imitate its protective effects — we may be able to preserve beta cell function longer or even prevent the onset of type 1 diabetes in people at risk,' he said. 'Our research offers a new path for scientists to explore how to make beta cells more resilient in an autoimmune environment.' Dr. Lu shared the findings of his study, 'BNIP3-mediated Mitophagy Protects Human Beta Cells by Regulating Mitochondrial Integrity and Immunogenicity in Type 1 Diabetes,' during an oral presentation on June 20 from 2 to 2:15 p.m. CT. Special Note: Dr. Lu earned the Young Investigator Award from the American Diabetes Association for his top-scoring work above. He works in the lab of Adolfo Garcia-Ocaña, Ph.D., City of Hope's Ruth B. and Robert K. Lanman Chair in Gene Regulation & Drug Discovery Research and chair of the Department of Molecular & Cellular Endocrinology. Interferons Influence RNA Activity in Beta Cells Two type-1 interferons, IFN-alpha and IFN-gamma, promote inflammation and play a key role in the early development of type 1 diabetes. Until now, how these signaling molecules shape the way insulin-producing cells read and use their genetic information had not been tested. 'We aimed to investigate how exposure of different pro-inflammatory cytokines alters the RNA epitranscriptome in human pancreatic islets and how these modifications affect protein synthesis under conditions of cellular stress,' explained City of Hope's Farooq Syed, Ph.D., assistant professor in the Department of Diabetes Immunology at the Arthur Riggs Diabetes & Metabolism Research Institute. To mimic early disease, Dr. Syed and colleagues treated human pancreatic islet cells — clusters of hormone producing cells that includes insulin secreting β cells — with IFN-alpha and IFN-gamma for eight and 24 hours and subjected them to RNA sequencing. Using a variety of techniques, the lab discovered different cytokines have selective impacts on RNA modifications and activated the integrated stress response (ISR) pathway. Scientists also pinpointed time- and cytokine-specific changes in RNA modifications. IFN-alpha treatment induced widespread m6A methylation changes, affecting 1,688 of 4,006 unique sites at eight hours and 14 of 936 sites at 24 hours. IFN-gamma similarly altered 639 of 2,527 sites at eight hours and 65 of 664 at 24 hours. Notably, 95 sites were consistently modified across all treatment conditions, many of which were linked to activation of the cellular stress response. 'We identified epitranscriptomic alterations in genes activated during defective messenger RNA translation, as well as in genes involved in beta-cell dysfunction and immune response,' Dr. Syed said. In a preclinical model, treatment with a drug that inhibited the cellular stress response led to a 70% reduction compared to the vehicle treated control group. Importantly, the treatment also restored mRNA translation in the pancreatic beta cells. 'Our findings show how inflammation activates the integrated stress response that drives RNA changes and disrupts messenger RNA translation in the beta cells. The process happens over time and selective cytokine specific manner,' said Dr. Syed. 'The results suggest that targeting the ISR pathway may hold promise as a therapeutic approach for type 1 diabetes.' He presented his abstract, ' Temporal Dynamics of RNA Modifications and Translation in Type I Interferon Stimulated Human,' during an oral presentation on June 20 from 1:15 to 1:30 p.m. CT. Why Tolerating Cold Is Harder as We Age Recent advances in single-cell technologies have uncovered complex cellular heterogeneity, yet it remains unclear whether this translates into functional diversity and how it affects tissue activity. A City of Hope preclinical study led by staff scientist Anying Song explored how distinct populations of brown fat cells contribute to heat production and energy regulation. The research focused on uncovering why thermogenic activity declines over time, revealing an immune-neural mechanism that drives this process and becomes impaired with aging. Song and associates had previously identified a subgroup of brown fat cells that express low levels of uncoupling protein 1 (UCP1), coexist with typical brown fat cells exhibiting high UCP1 levels. 'The UCP1 generates heat by burning fat,' said Song, who works in the lab of Qiong (Annabel) Wang, Ph.D., associate professor in the Department of Molecular & Cellular Endocrinology, Diabetes and Metabolism Research Institute. 'Brown fat cells burn energy, while white fat cells store it.' The team discovered a population of immune cells that secrete interleukin-1 beta (IL-1β), which acts locally to lower the heat production in adjacent brown fat cells. IL-1β protects a protein called H6PD from breaking down; this enhances local glucocorticoid activation, which in turn signals hormone receptors to suppress the expression of the uncoupling protein 1. Cold temperatures reduced IL-1β levels and speeds up activity in brown fat cells to generate heat. 'When we removed the hormone receptor during cold exposure, the brown fat cells couldn't slow their activity as it grew warmer,' explained Song. 'This kept heat production going.' 'As we age, IL-1β levels rise, leading to a lower ratio of active to inactive brown fat cells and making it harder to tolerate the cold,' explained Song. Reducing the hormone receptor signaling in older mice helped restore the balance between active and inactive brown fat and boosted heat production. 'Our findings demonstrate how different types of brown fat cells work together over time and space to control heat production in the body,' said Song. 'This mechanism integrates neural and immune signals and becomes dysregulated with age, contributing to the aging of brown fat tissue Understanding this process opens new avenues for improving metabolic health and could lead to better strategies for preventing or treating conditions like type 2 diabetes.' Song discussed the study, titled 'Bistable Regulation of Cellular Heterogeneity Governs Thermogenic Activity,' during an oral presentation on June 21 from 2:45 to 3 p.m. CT. How Prediabetes Develops into Type 2 Diabetes More than 35% of the U.S. population over age 18 has prediabetes, the precursor to type 2 diabetes (T2D). Exactly how prediabetes advances to T2D is unclear, but scientists suspect a disruption of how the body metabolizes food for energy plays a role. This metabolic dysfunction creates toxic byproducts that attach to DNA, RNA and proteins, altering how they work. Research, led by Kassandra Lopez, a Ph.D. candidate, scrutinized how MG-adducts, a metabolic byproduct made from methylglyoxal, change the function of insulin-producing beta cells in the pancreas. 'We suspect MG-adducts build up during pre-diabetes and drive progression to type 2 diabetes by damaging DNA and blocking beta cells' ability to release insulin when needed,' said Lopez, who works in the laboratory of Sarah Shuck, Ph.D., assistant professor, Department of Diabetes & Cancer Metabolism, Arthur Riggs Diabetes & Metabolism Institute The researchers utilized a novel liquid chromatography tandem mass spectrometry method to measure MG-adducts in cells, tissues, urine and blood. The team also examined DNA breakage and monitored the production of destructive molecules. Their early findings link high blood sugar to the accumulation of MG-adducts in pancreatic beta cells, especially in people diagnosed with prediabetes and T2D. The combination of high blood sugar and MG-adducts also increased DNA damage to beta cells, undermining their ability to secrete insulin. 'Our study is the first to measure methylglyoxal and its harmful byproducts in people with prediabetes,' said Lopez. 'We believe our novel approach offers a unique opportunity to decipher how MG-adducts are linked to the progression of type 2 diabetes.' Lopez will present her research poster, 'Elucidating the Role of Reactive Metabolic By-Products as Predictors and Drivers of Type 2 Diabetes,' on June 23 from 1:30 to 2:30 pm. Additional presentations by City of Hope scientists at the meeting include those listed below. Alberto Pugliese, M.D. — the Samuel Rahbar Chair in Diabetes & Drug Discovery, chair, Department of Diabetes Immunology, Arthur Riggs Diabetes & Metabolism Research Institute at City of Hope — lead an advisory panel on viral T-cell responses on June 21 from 3:55 – 4:05 p.m. CT. Location: W192 A-C. Poster presentation sessions on June 23 from 12:30 to 1:30 p.m. CT will include: Human Alpha-cell Heterogeneity and Trajectory Inference Analyses of Human Islets Reveal SMOC1 as a Beta-Cell Dedifferentiation Gene [Board No. 1846] by Randy Kang, senior research associate Dual Roles of Renal Tubular Mitochondrial AKT1 in Improving Whole Body Glucose Metabolism and Protecting Against Diabetic Nephropathy [Board No. 380] by Esam Salem, postdoctoral fellow Selective Induction of Spliced XBP1 in Pancreatic Islet Beta Cells Causes Reversible Diabetes [Board No. 1831] by Yingfeng Deng, Ph.D. assistant professor, Department of Diabetes, & Cancer Metabolism About City of Hope City of Hope's mission is to make hope a reality for all touched by cancer and diabetes. Founded in 1913, City of Hope has grown into one of the largest and most advanced cancer research and treatment organizations in the United States, and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center that is ranked a Top 5 'Best Hospital' in the nation for cancer care by U.S. News & World Report at its core, City of Hope's uniquely integrated model spans cancer care, research and development, academics and training, and a broad philanthropy program that powers its work. City of Hope's growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and cancer treatment centers and outpatient facilities in the Atlanta, Chicago and Phoenix areas. City of Hope's affiliated group of organizations includes Translational Genomics Research Institute and AccessHope TM. For more information about City of Hope, follow us on Facebook, X, YouTube, Instagram and LinkedIn.
Business Wire
2 hours ago
- Business Wire
Washington Post Ranks Aledade as Top Workplace for Sixth Consecutive Year
BETHESDA, Md.--(BUSINESS WIRE)--The Washington Post has recognized Aledade, the nation's largest network of independent value-based primary care, among the best companies to work for in their annual Top Workplaces rankings. "At Aledade, we have a talented and deeply committed team working across the country to make our mission a reality," said Helena Christianson, Aledade's chief people officer. Share Aledade was ranked seventh in The Washington Post's largest employer category for the District of Columbia area. Aledade earned The Washington Post's top employer ranking for the sixth consecutive year. Selection for the Post's honor is based on employee feedback gathered through an anonymous third-party survey which measured several aspects of workplace culture, including alignment, execution and connection. Headquartered in Bethesda, Maryland with more than 1,400 employees across the United States, Aledade fosters a mission-centric workplace with remote-first flexibility. More than 90% of employees believe that the company lives out its mission to make the health care system better for patients, primary care practices and society. The company's commitment to employee wellbeing is demonstrated by offerings such as 12 weeks of fully paid parental leave for all new parents, generous paid time off, a fully paid six-week sabbatical for employees after six years of service and training and development programs. "At Aledade, we have a talented and deeply committed team working across the country to make our mission a reality," said Helena Christianson, Aledade's chief people officer. "We're deeply committed to sustaining an innovative environment and proud to support each and every employee with comprehensive benefits and programming for their growth and wellbeing." This recognition by The Washington Post adds to Aledade's growing list of accolades as a top employer. In 2024, Forbes magazine ranked Aledade as the No. 3 best health care industry startup employer in the United States while USA Today ranked Aledade No. 4 in its rankings of companies with between 1,000 and 2,499 employees. Additionally, Modern Healthcare ranked Aledade as one of the 2024 Best Places to Work in Healthcare. About Aledade Aledade, a public benefit corporation, is the largest network of independent primary care in the country, helping independent practices, health centers and clinics deliver better care to their patients and thrive in value-based care. Through its proven, scalable model, which includes cutting-edge data analytics, user-friendly guided workflows, health care policy expertise, strong payer relationships and integrated care solutions, Aledade empowers physicians to succeed financially by keeping people healthy. Together with more than 2,400 practices, federally-qualified health centers and community health centers in 46 states and the District of Columbia, Aledade shares in the risk and reward across more than 200 value-based contracts representing nearly 3.0 million patient lives under management. To learn more, visit or follow on X (Twitter), Facebook or LinkedIn.
Business Wire
3 hours ago
- Business Wire
LifePlus Establishes Global Clinical Validation for First-of-Its-Kind Non-Invasive Glucose and Cuffless BP Monitoring Device and Platform
SAN JOSE, Calif.--(BUSINESS WIRE)-- LifePlus, a Silicon Valley startup redefining personal health monitoring, today announced the clinical validation of LifeLeaf ®, the world's first non-invasive and cuffless wearable for continuous glucose and blood pressure tracking. The device, tested in global multi-center trials including Mayo Clinic, AMCR Clinic – San Diego, CA, Cleveland Clinic – Abu Dhabi, and Hospital Sebarang Jaya – Penang, Malaysia, delivers real-time insights without needles, invasive sensors, or cuffs, setting a new standard in scalable, preventive care management. LifeLeaf delivers clinically validated performance without the usual barriers of needles, cuffs, or cost. Share 'LifeLeaf delivers clinically validated performance without the usual barriers of needles, cuffs, or cost,' said Dr. Samuel J. Asirvatham and Dr. Narayan G. Kowlgi of Cardiovascular Medicine, Mayo Clinic, Rochester, MN. 'By making blood pressure and glucose monitoring effortless and non-invasive, it drives better patient adherence, which is crucial for managing chronic conditions like hypertension and diabetes. This scalable solution has a strong potential to transform care models globally by enabling proactive, patient-friendly disease management.' Global Dataset LifePlus has collected and analyzed over 70,000 paired multi-biomarker datapoints from more than 500 human subjects across 14 countries and 4 continents. 'This robust dataset spans a wide range of demographics—including skin tone, age, gender, and BMI—supporting the development of proprietary signal processing and highly generalizable, multi-biomarker advanced AI/ML algorithms and models,' said Ben Mbouombouo, Chief Operating Officer and Product GM of LifePlus. Clinical Results LifePlus has already conducted multiple clinical studies to demonstrate clinical validation for LifeLeaf. The most recent results of its performance vs BGM for glucose monitoring are scheduled to be showcased at the upcoming American Diabetes Association (ADA) Meeting, June 20-23, 2025. Earlier, LifeLeaf's performance vs CGM was shared at the Advanced Technology and Treatment for Diabetes (ATTD) meeting in 2023. LifePlus also published clinical validation results for blood pressure in the European Society of Hypertension meeting in 2023. Please see key highlights below: Glucose Monitoring In head-to-head studies, LifeLeaf achieved an impressive 10.8% MARD against BGM references 1 and 8.5% MARD against Dexcom G6 2 for a target dynamic range of 70-250 mg/dL, demonstrating non-invasive glucose monitoring is not only possible, but viable and scalable for real-world use. LifeLeaf attained a low 2% outlier rate 1 in blinded continuous glucose monitoring studies, comparable with invasive alternatives and underscoring its clinical reliability. Blood Pressure The cuffless blood pressure feature of LifeLeaf demonstrated impressive accuracy, with a mean difference ± standard deviation of –0.02 ± 12.5 mmHg for systolic and 0.03± 8.4 mmHg for diastolic measurements 3 for a supported dynamic range of 90/55-170/110 mmHg, validated across multiple clinical studies and real-world settings. LifeLeaf collected indefinite long-term blood pressure data as opposed to traditional ambulatory monitors, offering continuous, real-world views. LifePlus is engaged with the world's leading clinicians to establish a new longitudinal metric for assessing arterial stiffness that may better predict long-term effects of hypertension and related cardiovascular outcomes. LifeLeaf is unique because it does not require needles, cuffs, or calibration as current solutions do. It is 70% more cost-effective over a 12-month period and supports effortless daily use, which is critical for maintaining a high degree of patient adherence and delivering preventive insights. 'The results presented at ADA this year show that LifeLeaf has the potential to provide accurate data, without invasiveness or complexity,' said Dr. Timothy S. Bailey of Headlands Research – AMCR Clinic, Escondido, CA, and Dr. Jerome S. Fischer of MDRequest, San Antonio, TX. 'This kind of non-invasive monitoring is uniquely poised to improve patient adherence and enable earlier detection – two critical factors in managing chronic conditions.' Upcoming Global Clinical Trials LifePlus is now initiating additional longitudinal outcome studies for LifeLeaf across Asia, Europe, Middle East and North America, focusing on prediabetic and hypertensive populations. The goal: to prove that continuous, passive monitoring can lead to earlier interventions and measurable reductions in chronic disease incidence. 'We're incredibly encouraged by the clinical validation at world-class institutions like Mayo Clinic and Cleveland Clinic,' said Dr. Alodeep Sanyal, co-founder and CEO of LifePlus. 'It confirms what we have believed from the beginning: that non-invasive, AI-powered monitoring can be reliable and scalable. The growing global interest from healthcare providers, partners and investors reaffirms that we are at the forefront of a major shift in how we manage and prevent chronic disease.' With global spending on diabetes and cardiovascular care projected to exceed $1.5 trillion annually by 2030, the market is primed for solutions that go beyond reactive treatment. LifeLeaf is the first clinically validated solution of its kind in this space, targeting a $100B+ total addressable market. To learn more about partnership, pilot opportunities, or investment in LifeLeaf's clinically validated platform, visit Footnotes 1. Improved accuracy of a fully non-invasive continuous glucose monitor in a diverse population. T. Bailey et al. American Diabetes Association (ADA) Annual Meeting 2025. 2. The feasibility of non-invasive continuous glucose monitoring with the novel LifeLeaf wristwatch and platform. T. Bailey et al. Advanced Technology and Treatment in Diabetes (ATTD) Annual Meeting 2023. 3. The feasibility of cuffless, non-occlusive blood pressure assessments using the novel LifeLeaf wristwatch and platform. European Society of Hypertension (ESH) Annual Meeting 2023. About LifePlus LifePlus is committed to transforming how people manage and improve their health. At the heart of our innovation is LifeLeaf ®, the world's first non-invasive, effortless, wrist-worn medical device and platform for continuous, real-time remote patient monitoring. Powered by AI, this technology empowers individuals with real-time insights into their vital health parameters, enabling proactive health management, early intervention, and seamless information sharing with loved ones and care teams. Designed for the billions worldwide at risk of chronic diseases, LifePlus is redefining everyday health monitoring with comfort, continuity, and confidence.
